Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China

Chinese biotech Biokin said its EGFRxHER3 bispecific antibody-drug conjugate passed a late-stage China trial in a genetically-defined form of lung cancer, buoying optimism for a similar global study led by its partner Bristol Myers Squibb. ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Other reports of this story

Every outlet that reported this, and when →

Read the original at endpoints.news →

More in Health & Medicine

More from Wednesday 19 August →